AbbVie Stock Declines 5% on New Competitive Threat
Shares of AbbVie (NYSE: ABBV) fell 5% on March 18 after the U.S. Food and Drug Administration (FDA) approved Icotyde, a new psoriasis treatment from Johnson & Johnson. The approval introduces a significant competitive threat to AbbVie's blockbuster drug, Skyrizi. Icotyde is a once-daily oral pill, a far more convenient administration method compared to Skyrizi, which is delivered via injection. This difference in patient convenience is the primary driver behind the immediate negative market reaction for AbbVie, as it could lead to rapid market share erosion for one of its key products.
J&J's Icotyde Poised to Capture Market with $5B+ Sales Forecast
Johnson & Johnson's Icotyde is the first targeted oral peptide that blocks the IL-23 receptor, a proven mechanism for treating plaque psoriasis. The drug's approval is supported by robust clinical data from its ICONIC development program, where head-to-head trials showed its superiority over existing oral treatments. In Phase 3 studies, approximately 70% of patients taking Icotyde achieved clear or almost clear skin. The combination of high efficacy and oral delivery has led analysts to project blockbuster status for the drug, with peak sales forecasts ranging from $5.5 billion (Citi) to $7.5 billion (Jefferies), while Johnson & Johnson itself anticipates sales of $5 billion or more.
Skyrizi's Growth Engine Faces Post-Humira Pressure
This new competition directly challenges AbbVie's long-term strategy. The company has been relying on Skyrizi as a primary growth driver to offset the massive revenue loss from the recent patent expiration of Humira, once the world's best-selling drug. With Icotyde positioned as a highly effective and more convenient alternative, AbbVie now faces intensified pressure on a revenue stream it depends on for future growth. Johnson & Johnson plans to expand Icotyde's applications to other immunology indications, including psoriatic arthritis and Crohn's disease, further threatening AbbVie's dominance in the immunology market.
